Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.82
JAZZ's Cash to Debt is ranked lower than
83% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. JAZZ: 0.82 )
Ranked among companies with meaningful Cash to Debt only.
JAZZ' s Cash to Debt Range Over the Past 10 Years
Min: 0.13  Med: 0.85 Max: No Debt
Current: 0.82
Equity to Asset 0.48
JAZZ's Equity to Asset is ranked lower than
73% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. JAZZ: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
JAZZ' s Equity to Asset Range Over the Past 10 Years
Min: -0.82  Med: 0.27 Max: 0.76
Current: 0.48
-0.82
0.76
Interest Coverage 8.93
JAZZ's Interest Coverage is ranked lower than
82% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. JAZZ: 8.93 )
Ranked among companies with meaningful Interest Coverage only.
JAZZ' s Interest Coverage Range Over the Past 10 Years
Min: 0.7  Med: 8.93 Max: 76.32
Current: 8.93
0.7
76.32
F-Score: 7
Z-Score: 4.42
M-Score: -2.62
WACC vs ROIC
8.00%
20.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 38.36
JAZZ's Operating margin (%) is ranked higher than
93% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. JAZZ: 38.36 )
Ranked among companies with meaningful Operating margin (%) only.
JAZZ' s Operating margin (%) Range Over the Past 10 Years
Min: -252.34  Med: 24.97 Max: 46.95
Current: 38.36
-252.34
46.95
Net-margin (%) 24.87
JAZZ's Net-margin (%) is ranked higher than
90% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. JAZZ: 24.87 )
Ranked among companies with meaningful Net-margin (%) only.
JAZZ' s Net-margin (%) Range Over the Past 10 Years
Min: -273.04  Med: 11.92 Max: 49.25
Current: 24.87
-273.04
49.25
ROE (%) 22.62
JAZZ's ROE (%) is ranked higher than
93% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. JAZZ: 22.62 )
Ranked among companies with meaningful ROE (%) only.
JAZZ' s ROE (%) Range Over the Past 10 Years
Min: 4.38  Med: 22.19 Max: 111.92
Current: 22.62
4.38
111.92
ROA (%) 9.81
JAZZ's ROA (%) is ranked higher than
89% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. JAZZ: 9.81 )
Ranked among companies with meaningful ROA (%) only.
JAZZ' s ROA (%) Range Over the Past 10 Years
Min: -113.42  Med: 5.97 Max: 64.21
Current: 9.81
-113.42
64.21
ROC (Joel Greenblatt) (%) 278.46
JAZZ's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. JAZZ: 278.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
JAZZ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5278.54  Med: 583.84 Max: 11377.93
Current: 278.46
-5278.54
11377.93
Revenue Growth (3Y)(%) 29.20
JAZZ's Revenue Growth (3Y)(%) is ranked higher than
81% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. JAZZ: 29.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
JAZZ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.3  Med: 29.70 Max: 47.7
Current: 29.2
-2.3
47.7
EBITDA Growth (3Y)(%) 29.90
JAZZ's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. JAZZ: 29.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
JAZZ' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 3.8  Med: 29.90 Max: 74.9
Current: 29.9
3.8
74.9
EPS Growth (3Y)(%) 6.40
JAZZ's EPS Growth (3Y)(%) is ranked higher than
63% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. JAZZ: 6.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
JAZZ' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.5  Med: 4.40 Max: 61.6
Current: 6.4
-66.5
61.6
» JAZZ's 10-Y Financials

Financials (Next Earnings Date: 2016-05-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

JAZZ Guru Trades in Q2 2015

Jim Simons 18,300 sh (New)
NWQ Managers 126,680 sh (+95.42%)
Ken Fisher 1,300 sh (unchged)
Steve Mandel Sold Out
Pioneer Investments 322,324 sh (-0.19%)
RS Investment Management 212,193 sh (-15.28%)
Joel Greenblatt 3,565 sh (-67.22%)
» More
Q3 2015

JAZZ Guru Trades in Q3 2015

Paul Tudor Jones 5,531 sh (New)
Steven Cohen 21,915 sh (New)
Joel Greenblatt 25,672 sh (+620.11%)
Jim Simons 124,300 sh (+579.23%)
RS Investment Management 317,133 sh (+49.45%)
Ken Fisher 1,725 sh (+32.69%)
Pioneer Investments 334,648 sh (+3.82%)
NWQ Managers 123,720 sh (-2.34%)
» More
Q4 2015

JAZZ Guru Trades in Q4 2015

George Soros 3,200 sh (New)
Louis Moore Bacon 35,000 sh (New)
Joel Greenblatt 184,961 sh (+620.48%)
Paul Tudor Jones 6,788 sh (+22.73%)
RS Investment Management 359,125 sh (+13.24%)
Pioneer Investments 363,799 sh (+8.71%)
Ken Fisher 1,859 sh (+7.77%)
NWQ Managers Sold Out
Steven Cohen Sold Out
Jim Simons 18,800 sh (-84.88%)
» More
Q1 2016

JAZZ Guru Trades in Q1 2016

Ken Fisher 1,949 sh (+4.84%)
» More
» Details

Insider Trades

Latest Guru Trades with JAZZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Jazz Pharmaceuticals PLC

Stocks Fisher Investments Has Bought for Past 2 Quarters Fisher adds to stake in Colgate and Energizer
Ken Fisher (Trades, Portfolio) is the CEO and CIO of Fisher Investments. The investment philosophy at Fisher Investments is based on the idea that supply and demand of securities is the sole determinate of pricing. The following are the companies the investor has been buying for at least the last two quarters. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 29.12
JAZZ's P/E(ttm) is ranked higher than
53% of the 239 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. JAZZ: 29.12 )
Ranked among companies with meaningful P/E(ttm) only.
JAZZ' s P/E(ttm) Range Over the Past 10 Years
Min: 10.72  Med: 25.77 Max: 415.7
Current: 29.12
10.72
415.7
Forward P/E 12.12
JAZZ's Forward P/E is ranked higher than
73% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 17.79 vs. JAZZ: 12.12 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 29.12
JAZZ's PE(NRI) is ranked higher than
53% of the 242 Companies
in the Global Biotechnology industry.

( Industry Median: 30.06 vs. JAZZ: 29.12 )
Ranked among companies with meaningful PE(NRI) only.
JAZZ' s PE(NRI) Range Over the Past 10 Years
Min: 11.86  Med: 25.59 Max: 411.84
Current: 29.12
11.86
411.84
Price/Owner Earnings (ttm) 24.03
JAZZ's Price/Owner Earnings (ttm) is ranked higher than
65% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 36.86 vs. JAZZ: 24.03 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
JAZZ' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.34  Med: 21.13 Max: 226.17
Current: 24.03
8.34
226.17
P/B 5.90
JAZZ's P/B is ranked lower than
70% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. JAZZ: 5.90 )
Ranked among companies with meaningful P/B only.
JAZZ' s P/B Range Over the Past 10 Years
Min: 2.46  Med: 6.33 Max: 32
Current: 5.9
2.46
32
P/S 7.26
JAZZ's P/S is ranked higher than
62% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. JAZZ: 7.26 )
Ranked among companies with meaningful P/S only.
JAZZ' s P/S Range Over the Past 10 Years
Min: 0.21  Med: 5.84 Max: 12
Current: 7.26
0.21
12
PFCF 19.36
JAZZ's PFCF is ranked higher than
66% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 30.80 vs. JAZZ: 19.36 )
Ranked among companies with meaningful PFCF only.
JAZZ' s PFCF Range Over the Past 10 Years
Min: 11.77  Med: 17.68 Max: 91.05
Current: 19.36
11.77
91.05
POCF 18.09
JAZZ's POCF is ranked higher than
63% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. JAZZ: 18.09 )
Ranked among companies with meaningful POCF only.
JAZZ' s POCF Range Over the Past 10 Years
Min: 9.59  Med: 16.55 Max: 55.21
Current: 18.09
9.59
55.21
EV-to-EBIT 18.80
JAZZ's EV-to-EBIT is ranked higher than
59% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. JAZZ: 18.80 )
Ranked among companies with meaningful EV-to-EBIT only.
JAZZ' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.5  Med: 16.40 Max: 74.1
Current: 18.8
-8.5
74.1
EV-to-EBITDA 15.50
JAZZ's EV-to-EBITDA is ranked higher than
58% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. JAZZ: 15.50 )
Ranked among companies with meaningful EV-to-EBITDA only.
JAZZ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.9  Med: 13.35 Max: 42.2
Current: 15.5
-10.9
42.2
PEG 0.78
JAZZ's PEG is ranked higher than
82% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 2.25 vs. JAZZ: 0.78 )
Ranked among companies with meaningful PEG only.
JAZZ' s PEG Range Over the Past 10 Years
Min: 0.61  Med: 1.15 Max: 8.62
Current: 0.78
0.61
8.62
Current Ratio 5.55
JAZZ's Current Ratio is ranked higher than
57% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. JAZZ: 5.55 )
Ranked among companies with meaningful Current Ratio only.
JAZZ' s Current Ratio Range Over the Past 10 Years
Min: 0.25  Med: 3.00 Max: 5.55
Current: 5.55
0.25
5.55
Quick Ratio 5.46
JAZZ's Quick Ratio is ranked higher than
58% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. JAZZ: 5.46 )
Ranked among companies with meaningful Quick Ratio only.
JAZZ' s Quick Ratio Range Over the Past 10 Years
Min: 0.23  Med: 2.90 Max: 5.46
Current: 5.46
0.23
5.46
Days Inventory 100.38
JAZZ's Days Inventory is ranked higher than
58% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. JAZZ: 100.38 )
Ranked among companies with meaningful Days Inventory only.
JAZZ' s Days Inventory Range Over the Past 10 Years
Min: 70.82  Med: 103.00 Max: 164.69
Current: 100.38
70.82
164.69
Days Sales Outstanding 57.77
JAZZ's Days Sales Outstanding is ranked higher than
56% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. JAZZ: 57.77 )
Ranked among companies with meaningful Days Sales Outstanding only.
JAZZ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.12  Med: 46.23 Max: 58
Current: 57.77
30.12
58
Days Payable 77.63
JAZZ's Days Payable is ranked higher than
57% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. JAZZ: 77.63 )
Ranked among companies with meaningful Days Payable only.
JAZZ' s Days Payable Range Over the Past 10 Years
Min: 73.94  Med: 81.91 Max: 285.12
Current: 77.63
73.94
285.12

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.07
JAZZ's Price/Projected FCF is ranked higher than
70% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 3.66 vs. JAZZ: 2.07 )
Ranked among companies with meaningful Price/Projected FCF only.
JAZZ' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.9  Med: 3.22 Max: 55.99
Current: 2.07
1.9
55.99
Price/Median PS Value 1.24
JAZZ's Price/Median PS Value is ranked lower than
67% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. JAZZ: 1.24 )
Ranked among companies with meaningful Price/Median PS Value only.
JAZZ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 0.94 Max: 1.53
Current: 1.24
0.12
1.53
Price/Peter Lynch Fair Value 1.17
JAZZ's Price/Peter Lynch Fair Value is ranked higher than
68% of the 57 Companies
in the Global Biotechnology industry.

( Industry Median: 1.86 vs. JAZZ: 1.17 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
JAZZ' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.08  Med: 5.50 Max: 9.92
Current: 1.17
1.08
9.92
Earnings Yield (Greenblatt) (%) 5.32
JAZZ's Earnings Yield (Greenblatt) (%) is ranked higher than
88% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. JAZZ: 5.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
JAZZ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.3  Med: 5.60 Max: 10.7
Current: 5.32
1.3
10.7
Forward Rate of Return (Yacktman) (%) 38.60
JAZZ's Forward Rate of Return (Yacktman) (%) is ranked higher than
86% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 13.93 vs. JAZZ: 38.60 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
JAZZ' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -43.1  Med: 1.50 Max: 49.5
Current: 38.6
-43.1
49.5

More Statistics

Revenue(Mil) $1325
EPS $ 5.23
Beta0.97
Short Percentage of Float3.89%
52-Week Range $108.50 - 194.73
Shares Outstanding(Mil)60.44

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 1,522 1,755 1,980
EPS($) 10.83 12.58 14.92
EPS without NRI($) 10.83 12.58 14.92

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:GILD, NAS:AMGN, NAS:CELG, NAS:BIIB » details
Traded in other countries:J7Z.Germany,
Jazz Pharmaceuticals PLC was originally incorporated in California in March 2003 and was reincorporated in Delaware in January 2004. The Company was originally formed as a private limited liability company in March 2005 under the name Azur Pharma Limited, and was subsequently re-registered as a public limited company under the name Azur Pharma Public Limited Company in October 2011. On January 18, 2012, the business of Jazz Pharmaceuticals, Inc. and Azur Pharma were combined in the Azur Merger in connection with which Azur Pharma was re-named Jazz Pharmaceuticals plc. It is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. Its products includes Xyrem, Erwinaze, Prialt. Its commercial activities in the United States are dedicated to its marketed products Xyrem, Erwinaze, Prialt, FazaClo HD, FazaClo LD and Versacloz, as well as providing support for sales of certain of its other products. They have approximately 180 trained, experienced sales professionals who detail its marketed products to physicians in specialties appropriate for each marketed product in the United States. In Europe, they promote Erwinase to hematology and oncology specialists. The Company's commercial activities include marketing and related services and commercial support services. The Company also employ third party vendors, such as advertising agencies, market research firms and suppliers of marketing and other sales support related services, to assist with its commercial activities. Some of these competitors include Endo Health Solutions Inc., Forest Laboratories, Inc., Shire Pharmaceuticals, Inc., Teva and Valeant. Other than the manufacturing plant in Italy where they produce some active pharmaceutical ingredients, including the defibrotide drug substance, discussed in more detail below, the company do not have its own manufacturing capability for its products or product candidates, or their active pharmaceutical ingredients, or the capability to package its products. The research, testing, manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, sale, distribution, recordkeeping, importing and exporting of pharmaceutical products are subject to extensive regulation by the FDA, the European Commission and other regulatory authorities, and regulations differ from country to country. In the United States, the FDA, under the Federal Food, Drug and Cosmetic Act, or FDCA, and its implementing regulations, regulates the review, approval, manufacturing and marketing of pharmaceutical products.
» More Articles for JAZZ

Headlines

Articles On GuruFocus.com
Stocks Fisher Investments Has Bought for Past 2 Quarters May 03 2016 
Citigroup, Amgen Are Trading With Wide Margin of Safety Mar 30 2016 
Weekly Insider Sells Highlight: MHK, JAZZ, BMY, ZAYO Mar 23 2015 
Pharmaceutical Giant Merck Buys Cubist Pharma Dec 09 2014 
Growth Momentum Should Continue For This Pharmaceutical Company Nov 15 2014 
Jazz Pharmaceuticals: Growth Trajectory Can Continue In Future Sep 03 2014 
Weekly CFO Sells Highlight: Google Inc, Jazz Pharmaceuticals PLC, Jack in the Box Inc. Jun 30 2014 
Weekly Insider Sells Highlight: JAZZ, HD, ESRX, SCI Mar 11 2014 
Weekly CFO Sells Highlight: Jazz Pharmaceuticals PLC, Carnival PLC, Juniper Networks Inc., Home Depo Mar 10 2014 
Jazz Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 08 2011 

More From Other Websites
What's Up at GW Pharmaceuticals (GWPH) in Q2 Earnings? May 03 2016
What's in Store for Agios (AGIO) This Earnings Season? May 03 2016
What Can We Expect from Jazz Pharmaceuticals in 2016? May 03 2016
How Did Jazz Pharmaceuticals’ Products Perform in 2015? Apr 26 2016
What Do Analysts Recommend for Jazz Pharmaceuticals? Apr 26 2016
Jazz Pharmaceuticals to Report 2016 First Quarter Financial Results on May 10, 2016 Apr 26 2016
Jazz Pharmaceuticals to Report 2016 First Quarter Financial Results on May 10, 2016 Apr 26 2016
Can Xyrem Maintain Leadership in the Narcolepsy Space? Apr 26 2016
Jazz Pharma upgraded by Sun Trust Rbsn Humphrey Apr 25 2016
Jazz Pharmaceuticals: How Does Its Earnings Multiple Compare? Apr 21 2016
Why Does Jazz Pharmaceuticals Have a Lower Valuation Than Peers? Apr 21 2016
Valeant CEO Is Brave; Clovis PT Slashed; Buy Jazz ‘Aggressively’? Apr 13 2016
[$$] Four Buys After the Specialty-Pharma Selloff Apr 08 2016
Final Trade: KB Homes, Jazz Pharmaceuticals, & more Apr 07 2016
The Allergan 'Dating Game' Apr 06 2016
Jazz Pharmaceuticals Plc – Value Analysis (NASDAQ:JAZZ) : April 1, 2016 Apr 01 2016
Jazz's Hepatic VOD Drug Defitelio Gains FDA Nod, Shares Up Mar 31 2016
Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : March... Mar 31 2016
Citigroup, Amgen Are Trading With Wide Margin of Safety Mar 30 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK